Explore more publications!

Latest News

Labels On
FILTER THE FEED
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
FILTER THE FEED
Source Label Filters

Select the labels to control what appears in your feed.

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore deal

Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore deal

Center-right The Economic Times
Owner: Sahu Jain Family
Allies unite at 20th Fuels Exchange Agreements Forum, forge stronger logistics bonds

Allies unite at 20th Fuels Exchange Agreements Forum, forge stronger logistics bonds

Novartis to lay off 550 workers at Swiss plant amid investment in automation

Novartis to lay off 550 workers at Swiss plant amid investment in automation

Swiss Hospitality Giant Anchors Gyumri Revival

Swiss Hospitality Giant Anchors Gyumri Revival

AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment

AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment

Eris Lifesciences to pick up remining 30% in Swiss Parenterals for ₹423 crore

Eris Lifesciences to pick up remining 30% in Swiss Parenterals for ₹423 crore

Neutral The Hindu Business Line
Owner: The Kasturi Family
As Brussels races to secure raw materials and cut its reliance on China, it's facing resistance from a Czech region that's thought to hold significant lithium deposits.

As Brussels races to secure raw materials and cut its reliance on China, it's facing resistance from a Czech region that's thought to hold significant lithium deposits.

Neutral The Parliament Magazine
Owner: Lord Michael Ashcroft
Allies unite at 20th Fuels Exchange Agreements Forum, forge stronger logistics bonds

Allies unite at 20th Fuels Exchange Agreements Forum, forge stronger logistics bonds

Novartis to lay off 550 workers at Swiss plant amid investment in automation

Novartis to lay off 550 workers at Swiss plant amid investment in automation

Swiss Hospitality Giant Anchors Gyumri Revival

Swiss Hospitality Giant Anchors Gyumri Revival

AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment

AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment

Eris Lifesciences to pick up remining 30% in Swiss Parenterals for ₹423 crore

Eris Lifesciences to pick up remining 30% in Swiss Parenterals for ₹423 crore

As Brussels races to secure raw materials and cut its reliance on China, it's facing resistance from a Czech region that's thought to hold significant lithium deposits.

As Brussels races to secure raw materials and cut its reliance on China, it's facing resistance from a Czech region that's thought to hold significant lithium deposits.

Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore deal

Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore deal

Show More

Video Stories

YouTube video thumbnail: Citywest Example of ‘Best Practice’ - EU Migration Chief
Play
Citywest Example of ‘Best Practice’ - EU Migration Chief
YouTube video thumbnail: US to cut Steel Tariffs Only if EU Agrees to Soften Digital Rules Enforcement in Return
Play
US to cut Steel Tariffs Only if EU Agrees to Soften Digital Rules Enforcement in Return
YouTube video thumbnail: How Does the EU's Plan Compare to Trump's Peace Plan for Ukraine?
Play
How Does the EU's Plan Compare to Trump's Peace Plan for Ukraine?
YouTube video thumbnail: EU Considering Ban on Weapons Sales to United Arab Emirates
Play
EU Considering Ban on Weapons Sales to United Arab Emirates

Video Title

Press Releases

FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

Show More
Your brand’s story is being written — with or without you.
We’re the leading press release service for mid-sized businesses & organizations built for the AI era.
Learn more

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions